Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 77, Issue 2, 2011, Pages 275-282

  Wahlang, Banrida ^a   Pawar, Yogesh B ^a   Bansal, Arvind K ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Accumulation; Caco 2 cells; Curcumin; Efflux; Metabolism; Permeability

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; CURCUMIN; CYTOCHROME P450 3A4; ITRACONAZOLE; VERAPAMIL;

ADSORPTION KINETICS; ARTICLE; CONFOCAL LASER MICROSCOPY; CYTOLYSIS; CYTOTOXICITY; DESORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TRANSPORT; EFFUSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MEMBRANE PERMEABILITY;

ABSORPTION; ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CALCITRIOL; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CURCUMIN; DRUG STABILITY; HUMANS; PERMEABILITY; SOLUBILITY;

EID: 79551514621     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.12.006     Document Type: Article

References (36)

1. G.K. Jayaprakasha, L. Jagan Mohan Rao, and K.K. Sakariah Chemistry and biological activities of C. longa Trends Food Sci. Technol. 16 12 2005 533 548
2. V. Lampe, and J. Milobedzka Studien über curcumin Ber. Dtsch. Chem. Ges. 46 1913 2235 2240
3. A. Goel, A.B. Kunnumakkara, and B.B. Aggarwal Curcumin as "Curecumin": from kitchen to clinic Biochem. Pharmacol. 75 4 2008 787 809
4. K.Y. Yang Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS J. Chromatogr. B 853 2007 183 189
5. R.A. Sharma, S.A. Euden, S.L. Platton, D.N. Cooke, A. Shafayat, H.R. Hewitt, T.H. Marczylo, B. Morgan, D. Hemingway, S.M. Plummer, M. Pirmohamed, A.J. Gescher, and W.P. Steward Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance Clin. Cancer Res. 10 20 2004 6847 6854
6. H.H. Tonnesen, M. Masson, and T. Loftsson Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability Int. J. Pharm. 244 1-2 2002 127 135
7. B.B. Aggarwal, A. Kumar, M.S. Aggarwal, and S. Shishodia Curcumin derived from turmeric (Curcuma longa): a spice for all seasons D. Bagchi, H.G. Preuss, Phytochemicals in Cancer Chemoprevention 2004 CRC Press Boca Raton, FL 349 387
8. C. Lao, M. Ruffin, D. Normolle, D. Heath, S. Murray, J. Bailey, M. Boggs, J. Crowell, C. Rock, and D. Brenner Dose escalation of a curcuminoid formulation BMC Complement Altern. Med. 6 1 2006 10
9. G. Garcea, D.J. Jones, R. Singh, A.R. Dennison, P.B. Farmer, R.A. Sharma, W.P. Steward, A.J. Gescher, and D.P. Berry Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration Br. J Cancer. 90 5 2004 1011 1015
10. C.R. Ireson, D.J.L. Jones, S. Orr, M.W.H. Coughtrie, D.J. Boocock, M.L. Williams, P.B. Farmer, W.P. Steward, and A.J. Gescher Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine Cancer Epidemiol. Biomarkers Prev. 11 1 2002 105 111
11. A. Asai, and T. Miyazawa Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma Life Sci. 67 23 2000 2785 2793
12. C. Ireson, S. Orr, D.J.L. Jones, R. Verschoyle, C.-K. Lim, J.-L. Luo, L. Howells, S. Plummer, R. Jukes, M. Williams, W.P. Steward, and A. Gescher Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production Cancer Res. 61 3 2001 1058 1064
13. Y.-J. Wang, M.-H. Pan, A.-L. Cheng, L.-I. Lin, Y.-S. Ho, C.-Y. Hsieh, and J.-K. Lin Stability of curcumin in buffer solutions and characterization of its degradation products J. Pharm. Biomed. Anal. 15 1996 1867 1876
14. H.H. Tonnesen, and J. Karlsen Studies on curcumin and curcuminoids. VI. Kinetics of curcumin degradation in aqueous solution Z. Lebensm. Unters. Forsch. 180 5 1985 402 404
15. D. Suresh, and K. Srinivasan Studies on the in vitro absorption of spice principles - curcumin, capsaicin and piperine in rat intestines Food Chem. Toxicol. 45 8 2007 1437 1442
16. Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, Guidance for Industry. "Waiver of In-vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System", 2000.
17. X.-L. Hou, K. Takahashi, N. Kinoshita, F. Qiu, K. Tanaka, K. Komatsu, K. Takahashi, and J. Azuma Possible inhibitory mechanism of Curcuma drugs on CYP3A4 in 1[alpha], 25 dihydroxyvitamin D3 treated Caco-2 cells Int. J. Pharm. 337 1-2 2007 169 177
18. D.A. Volpe, P.J. Faustino, A.B. Ciavarella, E.B. Asafu-Adjaye, C.D. Ellison, L.X. Yu, and A.S. Hussain Classification of drug permeability with a Caco-2 cell monolayer assay Clin. Res. Reg. Affairs 24 1 2007 39 47
19. B.T. Kurien, A. Singh, H. Matsumoto, and R.H. Scofield Improving the solubility and pharmacological efficacy of curcumin by heat treatment Assay Drug Dev. Technol. 5 4 2007 567 576
20. B.T. Kurien, and R.H. Scofield Curcumin/turmeric solubilized in sodium hydroxide inhibits HNE protein modification - an in vitro study J. Ethnopharmacol. 110 2 2007 368 373
21. K.A. Youdim, A. Avdeef, and N.J. Abbott In vitro trans-monolayer permeability calculations: often forgotten assumptions Drug Discov. Today 8 21 2003 997 1003
22. S. Yamashita, T. Furubayashib, M. Kataokaa, T. Sakanea, H. Sezaki, and H. Tokuda Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells Eur. J. Pharm. Sci. 10 2000 195 204
23. X.-L. Hou, K. Takahashi, K. Tanaka, K. Tougou, F. Qiu, K. Komatsu, K. Takahashi, and J. Azuma Curcuma drugs and curcumin regulate the expression and function of P-gp in Caco-2 cells in completely opposite ways Int. J. Pharm. 358 1-2 2008 224 229
24. M. Uchida, T. Fukazawa, Y. Yamazaki, H. Hashimoto, and Y. Miyamoto A modified fast (4 day) 96-well plate Caco-2 permeability assay J. Pharmacol. Toxicol. Methods 59 1 2009 39 43
25. T. Korjamo, P. Honkakoski, M.R. Toppinen, S. Niva, M. Reinisalo, J.J. Palmgren, and J. Monkkonen Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines Eur. J. Pharm. Sci. 26 3-4 2005 266 279
26. M. Bernabe-Pineda, M.T. Ramirez-Silva, M. Romero-Romo, E. Gonzalez-Vergara, and A. Rojas-Hernandez Determination of acidity constants of curcumin in aqueous solution and apparent rate constant of its decomposition Spectrochim. Acta A Mol. Biomol. Spectrosc. 60 2004 1091 1097
27. N. Maubon, M. Le Vee, L. Fossati, M. Audry, E. Le Ferrec, S. Bolze, and O. Fardel Analysis of drug transporter expression in human intestinal Caco-2 cells by real-time PCR Fundam. Clin. Pharmacol. 21 6 2007 659 663
28. V. Meunier, M. Bourrie, Y. Berger, and G. Fabre The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications Cell Biol. Toxicol. 11 3-4 1995 187 194
29. P. Schmiedlin-Ren, K.E. Thummel, J.M. Fisher, M.F. Paine, K.S. Lown, and P.B. Watkins Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha, 25-dihydroxyvitamin D3 Mol. Pharmacol. 51 1997 741 754
30. J.M. Fisher, S.A. Wrighton, P.B. Watkins, P. Schmiedlin-Ren, J.C. Calamia, D.D. Shen, K.L. Kunze, and K.E. Thummel First-pass midazolam metabolism catalyzed by 1alpha, 25-dihydroxy vitamin D3-modified Caco-2 cell monolayers J. Pharmacol. Exp. Ther. 289 2 1999 1134 1142
31. T.M.D. Mauro, Intranasally administering curcumin prodrugs to the brain to treat Alzheimer's disease, US Patent, US 2008/0076821 A1, 2008.
32. J.J. Johnson, and H. Mukhtar Curcumin for chemoprevention of colon cancer Cancer Lett. 255 2 2007 170 181
33. M. Lopez-Lazaro Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent Mol. Nutr. Food Res. 52 Suppl. 1 2008 S103 S127
34. C. Martin-Cordero, M. Lopez-Lazaro, M. Galvez, and M.J. Ayuso Curcumin as a DNA topoisomerase II poison J. Enzyme Inhib. Med. Chem. 18 6 2003 505 509
35. H. Wang, Y. Mao, A.Y. Chen, N. Zhou, E.J. LaVoie, and L.F. Liu Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation Biochemistry 40 11 2001 3316 3323
36. B.T. Kurien, A. D'Souza, and R.H. Scofield Heat-solubilized curry spice curcumin inhibits antibody-antigen interaction in in vitro studies: a possible therapy to alleviate autoimmune disorders Mol. Nutr. Food Res. 54 8 2010 1202 1209